Novartis is a multinational pharmaceutical company that is headquartered in Basel, Switzerland. The company's financial statements provide valuable insights into its financial health, performance, and overall operations.
For the year ended December 31, 2021, Novartis reported a net income of $12.4 billion, a significant increase from the previous year's net income of $10.6 billion. This increase can be attributed to the company's strong performance in its pharmaceuticals and generics divisions, which saw increased sales and profits.
One key financial indicator for Novartis is its revenue, which for the year ended December 31, 2021, was $53.7 billion. This represents a 2% increase from the previous year, demonstrating the company's ability to consistently generate income.
Another important financial metric for Novartis is its gross profit margin, which measures the percentage of revenue that is left after subtracting the cost of goods sold. For the year ended December 31, 2021, Novartis' gross profit margin was 72.2%, indicating that the company is able to generate significant profits from its operations.
Novartis also has a strong balance sheet, with total assets of $139 billion and total liabilities of $56 billion. This gives the company a net worth of $83 billion, which is a key measure of financial stability.
In terms of shareholder equity, Novartis has a strong track record of returning value to its shareholders through dividends and share buybacks. In 2021, the company paid out $5.2 billion in dividends and repurchased $5.4 billion of its own shares.
Overall, Novartis' financial statements demonstrate a strong, financially stable company that is able to generate consistent revenue and profits, and is committed to returning value to its shareholders.
What are NOVARTIS Financial Statements from 2010 to 2023
Nor can there be any guarantee that the strategic review being undertaken to maximize shareholder value of the Alcon Division will reach any particular results, or at any particular time, or that the result of the strategic review will in fact maximize shareholder value. Such forward looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. It highlights progress against our five strategic priorities and describes how we create value for diverse stakeholders. Because the greatest risk in life, is the risk of never trying! The digital and interactive version of the Annual Review is available Annual Report 2019 Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results. Cosentyx, our treatment for psoriasis and other autoimmune diseases, also continued to grow strongly. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
Novartis Annual Financial Statements last 10 years from 2010 to 2023
Neither can there be any guarantee that shareholders will achieve any particular level of shareholder returns. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for any existing products in any market, or that any approvals which are obtained will be obtained at any particular time, or that any such products will achieve any particular revenue levels. Neither can there be any guarantee that Novartis will be able to realize any of the potential strategic benefits, synergies or opportunities as a result of the significant acquisitions and reorganizations of recent years. Works with direct managers to support financial activities, decision making and general projects. Nor can there be any guarantee that the Group, or any of its divisions, will be commercially successful in the future, or achieve any particular credit rating or financial results. It also contains our operating and financial results, accompanied by audited annual financial statements. You should not place undue reliance on these statements.
